PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

MarketBeat • Aug 16, 2026

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

Seeking Alpha • Aug 13, 2026

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics Inc. (NASDAQ:PTCT) on Wednesday said it is expanding its rare disease portfolio through the planned acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics in a competitive bankruptcy auction.

Benzinga • Aug 13, 2026

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.

PRNewsWire • Aug 12, 2026

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • Aug 4, 2026

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Aug 4, 2026

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Jul 31, 2026

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.

PRNewsWire • Jul 30, 2026

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.

Zacks Investment Research • Jul 30, 2026